Stock Events

Stock Events

Boundless Bio 

$1.1
0
-$0.11-9.09% Friday 04:00

Statistics

Day High
1.1
Day Low
1.1
52W High
-
52W Low
-
Volume
3
Avg. Volume
-
Mkt Cap
24.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q3 2025
Q4 2025
Next
-0.62
-0.59
-0.55
-0.52
Expected EPS
-0.576667
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2023
2024
0Revenue
-130.73MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BOLD.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics focuses on gene editing technologies, directly competing in the genetic medicine space similar to Boundless Bio's approach to oncology.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine works on genome editing technology, which is a direct competitor to Boundless Bio's gene-targeting therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is involved in CRISPR/Cas9 technology, competing in the same gene editing sector as Boundless Bio.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics uses base editing technology, a form of gene editing that competes with Boundless Bio's precision oncology solutions.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing with Boundless Bio in the genetic approaches to disease.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics focuses on allogeneic CAR T-cell therapies, which are part of the broader field of genetic medicine, overlapping with Boundless Bio's market.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, competing in the genetic disorder treatment market like Boundless Bio.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics works on programmed cellular immunotherapies, which compete with Boundless Bio's focus on innovative biotechnologies for cancer treatment.
Adaptive Biotechnologies
ADPT
Mkt Cap2.64B
Adaptive Biotechnologies focuses on the immune-driven discovery and development of treatments, competing in the personalized medicine space with Boundless Bio.

About

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Show more...
CEO
ISIN
US10170A1007

Listings

XNAS
US
BOLD
BOATS
BOATS
BOLD.BOATS

0 Comments

Share your thoughts

FAQ

What is Boundless Bio stock price today?▼
The current price of BOLD.BOATS is $1.1 USD — it has decreased by -9.09% in the past 24 hours. Watch Boundless Bio stock price performance more closely on the chart.
What is Boundless Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Boundless Bio stocks are traded under the ticker BOLD.BOATS.
What is Boundless Bio market cap?▼
Today Boundless Bio has the market capitalization of 24.62M
When is the next Boundless Bio earnings date?▼
Boundless Bio is going to release the next earnings report on May 18, 2026.
What were Boundless Bio earnings last quarter?▼
BOLD.BOATS earnings for the last quarter are -0.58 USD per share, whereas the estimation was -0.52 USD resulting in a -11.54% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Boundless Bio revenue for the last year?▼
Boundless Bio revenue for the last year amounts to 0 USD.
What is Boundless Bio net income for the last year?▼
BOLD.BOATS net income for the last year is -130.73M USD.
When did Boundless Bio complete a stock split?▼
Boundless Bio has not had any recent stock splits.